Price · as of 2025-12-31
$26.45
Market cap 18.14B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $5.60 | -78.83% |
| Intrinsic Value(DCF) | $25.04 | -5.33% |
| Graham-Dodd Method(GD) | $16.60 | -37.24% |
| Graham Formula(GF) | $27.70 | +4.73% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.65 | $4.38 | $0.00 | $0.00 | $6.20 |
| 2012 | $1.83 | $5.04 | $0.17 | $0.00 | $0.00 |
| 2013 | $4.45 | $6.95 | $0.41 | $0.40 | $1.50 |
| 2014 | $7.71 | $8.26 | $6.96 | $1.00 | $2.90 |
| 2015 | $12.04 | $11.21 | $12.33 | $2.00 | $8.20 |
| 2016 | $20.04 | $15.12 | $22.67 | $2.80 | $20.40 |
| 2017 | $20.94 | $15.00 | $14.39 | $3.00 | $10.50 |
| 2018 | $17.29 | $13.85 | $22.30 | $3.90 | $13.10 |
| 2019 | $23.51 | $20.79 | $56.54 | $6.20 | $44.30 |
| 2020 | $32.89 | $34.29 | $1,028.97 | $10.30 | $106.10 |
| 2021 | $31.71 | $29.10 | $93.01 | $8.90 | $0.00 |
| 2022 | $34.88 | $40.24 | $279.18 | $13.10 | $101.20 |
| 2023 | $30.30 | $36.81 | $69.29 | $12.70 | $21.90 |
| 2024 | $24.14 | $38.66 | $143.41 | $17.80 | $71.20 |
| 2025 | $29.65 | $35.60 | $43.57 | $16.60 | $27.70 |
AI valuation
Our deep-learning model estimates Genmab A/S's (GMAB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $5.60
- Current price
- $26.45
- AI upside
- -78.83%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$25.04
-5.33% upside
Graham-Dodd
$16.60
-37.24% upside
Graham Formula
$27.70
+4.73% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GMAB | Genmab A/S | $26.45 | 18.14B | +35% | -5% | -37% | +5% | 19.14 | 3.16 | 4.95 | 16.85 | — | -5.09 | 91.69% | 33.60% | 25.89% | 16.63% | 16.30% | 9.62% | 0.95 | 20.49 | 2.02 | 2.01 | 2.90 | -1936.00% | 1023.00% | -336.00% | 6.23% | 0.83 | 18.73% | 0.00% | 0.00% | 2.33% | 17.81 | 19.37 | 5.98 | 2.77 |
| DGX | Quest Diagnostics Incorpo… | $211.91 | 23.57B | -3% | -58% | — | -18% | 22.31 | 3.25 | 2.11 | 13.60 | 161.86 | -6.84 | 31.93% | 14.53% | 8.99% | 15.00% | 9.14% | 6.46% | 0.96 | 6.07 | 1.04 | 0.80 | 2.96 | 1378.00% | 1178.00% | 4950.00% | 5.82% | 0.83 | 10.07% | 1.51% | 33.70% | 3.61% | 18.61 | 21.95 | 2.70 | 3.44 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| ILMN | Illumina, Inc. | $134.46 | 20.56B | -15% | -56% | -72% | -69% | 23.92 | 7.47 | 4.68 | 14.59 | — | 14.52 | 66.49% | 19.92% | 19.58% | 33.36% | 18.25% | 13.13% | 0.94 | 8.65 | 2.08 | 1.57 | 0.78 | -17074.00% | -69.00% | 3131.00% | 4.58% | 0.68 | 25.10% | 0.00% | 0.00% | 5.42% | 24.57 | 22.83 | 4.89 | 4.42 |
| INCY | Incyte Corporation | $101.27 | 20.15B | +47% | +302% | -42% | +85% | 15.18 | 3.78 | 3.80 | 9.10 | 0.36 | 3.97 | 91.47% | 26.12% | 25.03% | 29.87% | 69.44% | 20.75% | 0.01 | 553.03 | 3.32 | 3.04 | -1.72 | 417333.00% | 2122.00% | 44387.00% | 6.94% | 0.93 | 90.63% | 0.00% | 0.00% | 7.19% | 11.93 | 11.82 | 3.12 | 8.52 |
| ROIV | Roivant Sciences Ltd. | $28.94 | 20.71B | +3% | -75% | -82% | -98% | -22.84 | 1.74 | 280.39 | -3.06 | — | 1.74 | 96.86% | -3453.32% | -591.96% | -6.70% | 1167.58% | -5.64% | 0.02 | — | 33.47 | 32.71 | 2.38 | -10459.00% | -1119.00% | 1010.00% | -10.36% | -5.62 | 982.26% | 0.00% | 0.00% | 15.88% | -3.35 | -3.98 | 115.63 | 20.07 |
| RPRX | Royalty Pharma plc | $46.21 | 19.8B | +84% | -35% | -81% | -50% | 15.48 | 3.17 | 8.62 | 17.62 | 64.14 | 3.69 | 100.00% | 65.58% | 32.42% | 19.73% | 11.31% | 7.00% | 1.38 | 5.07 | 0.97 | 2.39 | 5.09 | 2414.00% | 506.00% | -1008.00% | 12.14% | 3.91 | 18.06% | 1.84% | 28.60% | 7.83% | 18.48 | 11.57 | 12.12 | 1.79 |
| SMMT | Summit Therapeutics Inc. | $16.59 | 12.35B | — | — | — | — | -11.21 | 18.37 | — | -14.24 | -3.08 | 18.43 | 0.00% | — | — | -206.10% | 2928.71% | -181.94% | 0.02 | — | 9.87 | 9.77 | 0.26 | 36452.00% | — | 12749.00% | -2.67% | -4.42 | 1166.77% | 0.00% | 0.00% | 0.93% | -14.04 | -35.25 | — | 72.96 |
| THC | Tenet Healthcare Corporat… | $239.39 | 21.04B | -32% | -53% | -100% | -28% | 15.18 | 5.06 | 1.00 | 7.36 | — | -2.57 | 41.41% | 16.46% | 6.60% | 33.54% | 19.78% | 4.80% | 3.12 | — | 1.76 | 1.22 | 2.39 | -5263.00% | 312.00% | 12670.00% | 11.85% | 0.79 | 16.87% | 0.00% | 0.00% | 11.50% | 9.02 | 12.51 | 1.48 | 2.07 |
| UTHR | United Therapeutics Corpo… | $503.90 | 22.79B | -28% | -44% | -38% | +9% | 17.05 | 3.21 | 7.15 | 11.66 | 130.50 | 3.26 | 87.92% | 46.89% | 41.94% | 19.71% | 25.78% | 17.51% | 0.00 | 76.54 | 6.60 | 3.40 | -0.86 | 1307.00% | 1061.00% | -369.00% | 4.57% | 2.78 | 23.09% | 0.00% | 0.00% | 5.10% | 14.21 | 20.38 | 6.66 | 20.45 |
| ZBH | Zimmer Biomet Holdings, I… | $98.44 | 19.51B | +4% | -60% | -82% | -46% | 27.93 | 1.55 | 2.39 | 12.01 | — | -10.06 | 61.62% | 16.55% | 8.57% | 5.60% | 6.12% | 3.17% | 0.59 | 4.65 | 1.98 | 0.89 | 3.12 | -1986.00% | 720.00% | 2887.00% | 7.47% | 0.66 | 7.80% | 0.97% | 27.00% | 3.44% | 19.55 | 18.08 | 3.23 | 1.82 |
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
- CEO
- Jan van de Winkel
- Employees
- 2.64K
- Beta
- 0.80
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($25.04 ÷ $26.45) − 1 = -5.33% (DCF, example).